利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.07 秒)

    Methods for treating a disease caused by choroidal neovascularization
    61.
    发明授权
    Methods for treating a disease caused by choroidal neovascularization 有权
    治疗由脉络膜新血管形成引起的疾病的方法

    公开(公告)号：US08975229B2

    公开(公告)日：2015-03-10

    申请号：US13377110

    申请日：2010-06-10

    申请人： Motokazu Tsujikawa ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Motokazu Tsujikawa ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： A61K38/00 ,  A61P35/00 ,  C07K14/515 ,  A61P9/10 ,  A61P27/02 ,  A61K38/08 ,  B60N2/225 ,  C07K14/00 ,  C07K14/71

    CPC分类号： B60N2/2252 ,  A61K38/00 ,  A61K38/179 ,  A61K39/0005 ,  A61K2039/55566 ,  C07K14/00 ,  C07K14/71

    摘要： The present invention provides novel pharmaceutical agents and methods for treating or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy). The present invention provides pharmaceutical compositions and vaccines for treating and/or preventing diseases caused by neovascularization in human choroid (neovascular maculopathy), comprising at least one type each of a peptide comprising an amino acid sequence derived from a VEGFR-1 protein and having an activity of inducing cytotoxic T cells, and a peptide comprising an amino acid sequence derived from a VEGFR-2 protein and having an activity of inducing cytotoxic T cells.

    摘要翻译： 本发明提供了用于治疗或预防由人类脉络膜（新生血管性黄斑病变）引起的新生血管形成的疾病的新型药剂和方法。 本发明提供用于治疗和/或预防由人类脉络膜（新生血管性黄斑病变）引起的新生血管形成的疾病的药物组合物和疫苗，其包含至少一种类型的肽，每种肽包含源自VEGFR-1蛋白的氨基酸序列， 诱导细胞毒性T细胞的活性，以及​​包含源自VEGFR-2蛋白质并具有诱导细胞毒性T细胞活性的氨基酸序列的肽。

    SMYD2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    63.
    发明申请
    SMYD2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
    SMYD2作为癌症治疗和诊断的靶基因

    公开(公告)号：US20140308678A1

    公开(公告)日：2014-10-16

    申请号：US14354813

    申请日：2012-06-29

    申请人： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57484 ,  C12Q1/689 ,  C12Q2600/158 ,  G01N33/57407

    摘要： The present invention arises from the discovery that the SMYD2 gene is both specifically over-expressed in cancer and involved in cancer cell survival. The present invention features methods for detecting or diagnosing the presence of or predisposition for developing cancer, using the SMYD2 gene as a diagnostic marker. The present invention further provides methods of screening for therapeutic substances useful in either or both of the treatment and prevention of cancer.

    摘要翻译： 本发明的起因于SMYD2基因在癌症中特异性过度表达并涉及癌细胞存活的发现。 本发明的特征在于使用SMYD2基因作为诊断标记来检测或诊断发展中的癌症的存在或倾向的方法。 本发明还提供筛选用于治疗和预防癌症的治疗物质的方法。

    CDC45L peptides and vaccines including the same
    65.
    发明授权
    CDC45L peptides and vaccines including the same 有权
    CDC45L肽和疫苗包括相同的

    公开(公告)号：US08586547B2

    公开(公告)日：2013-11-19

    申请号：US13321812

    申请日：2010-05-25

    申请人： Yasuharu Nishimura ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Yasuharu Nishimura ,  Yusuke Tomita ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： A61K38/08 ,  A61K38/04

    CPC分类号： C07K14/4748 ,  A61K39/0011 ,  A61K2039/5158

    摘要： The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 18, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of the present invention can be used for treating cancer.

    摘要翻译： 本发明提供分离的肽或衍生自SEQ ID NO：18的片段，其结合HLA抗原并诱导细胞毒性T淋巴细胞（CTL）。 肽可以包括一个上述氨基酸序列中的一个，两个或几个氨基酸序列的取代，缺失或添加。 本发明还提供包含这些肽的药物组合物。 本发明的肽可用于治疗癌症。

    WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS
    67.
    发明申请
    WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
    WHSC1和WHSC1L1用于靶向治疗癌症和诊断基因

    公开(公告)号：US20130137748A1

    公开(公告)日：2013-05-30

    申请号：US13576917

    申请日：2011-02-02

    申请人： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

    发明人： Ryuji Hamamoto ,  Yusuke Nakamura ,  Takuya Tsunoda

    IPC分类号： C12N15/113 ,  C12Q1/02 ,  G01N33/53

    CPC分类号： C12N15/1137 ,  A61K31/713 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/53

    摘要： Objective methods for diagnosing a predisposition to developing cancer, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma, are described herein. In one embodiment, the diagnostic method involves determining an expression level of a WHSC1 or WHSC1L1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of WHSC1 or WHSC1L1 associated disease, such as a cancer, e.g., bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of WHSC1 or WHSC1L1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them. Also, disclosed are methods of identifying substances for treating or/and preventing lung cancer, using as an index their effect on expression of a WHSC1 or WHSC1L1 gene, or a biological activity of a WHSC1 or WHSC1L1 polypeptide.

    摘要翻译： 用于诊断发展中癌症的倾向的客观方法，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤 ，在此描述。 在一个实施方案中，诊断方法包括确定WHSC1或WHSC1L1基因的表达水平。 本发明还提供筛选用于治疗WHSC1或WHSC1L1相关疾病的治疗剂的方法，例如癌症，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤 ，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤。 本发明还提供抑制细胞生长和治疗或减轻WHSC1或WHSC1L1相关疾病症状的方法。 本发明还包括产物，包括双链分子和编码它们的载体以及包括它们的组合物。 此外，公开了用于鉴定用于治疗或/和预防肺癌的物质的方法，以其对WHSC1或WHSC1L1基因表达的影响或WHSC1或WHSC1L1多肽的生物活性的指标。

    METHODS FOR DIAGNOSING OR TREATING PROSTATE CANCER
    69.
    发明申请
    METHODS FOR DIAGNOSING OR TREATING PROSTATE CANCER 失效
    用于诊断或治疗前列腺癌的方法

    公开(公告)号：US20110294123A1

    公开(公告)日：2011-12-01

    申请号：US13130284

    申请日：2009-11-18

    申请人： Yusuke Nakamura ,  Hidewaki Nakagawa ,  Takuya Tsunoda

    发明人： Yusuke Nakamura ,  Hidewaki Nakagawa ,  Takuya Tsunoda

    IPC分类号： C12Q1/68 ,  C07H21/00 ,  C07K16/18 ,  G01N33/577

    CPC分类号： C12Q1/6886 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q2600/112 ,  C12Q2600/136 ,  G01N33/57434 ,  G01N2500/04

    摘要： The present invention provides methods for detecting and/or diagnosing cancer through the determination of the expression level of the STC2 gene. The gene was discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer, methods for treating cancer. Moreover, the present invention provides double-stranded molecules targeting the STC2 gene, which are suggested to be useful in the treatment of cancer. The compositions and methods of the present invention find particular applicability to prostate cancer, more specifically, castration-resistant prostate cancer and aggressive prostate cancer.

    摘要翻译： 本发明提供了通过确定STC2基因的表达水平来检测和/或诊断癌症的方法。 发现该基因能够将癌细胞与正常细胞区分开来。 此外，本发明提供筛选用于治疗癌症的治疗剂的方法，用于治疗癌症的方法。 此外，本发明提供靶向STC2基因的双链分子，其被认为可用于治疗癌症。 本发明的组合物和方法特别适用于前列腺癌，更具体地说，抗阉割抗性前列腺癌和侵袭性前列腺癌。